Testo Cypmax

Description

General information about Testo-Cypmax in Belgium

TESTO-CYPMAX (testosterone cypionate) Injection, provides testosterone enanthate, a derivative of the primary androgenic endogenous testosterone.

Endogenous androgens are responsible for the normal growth and development of the male sex organs and the maintenance of secondary sex characteristics. These effects include growth and maturation of the prostate, seminal vesicles, penis and scrotum, Development of male hair distribution, such as beard, pubis, chest and axillary hair, Enlargement of the larynx, thickening of the vocal cords and alterations in body musculature and fat distribution. Drugs of this class also cause retention of nitrogen, sodium, potassium and phosphorus and decreased urinary calcium excretion. Androgens have been reported to increase protein anabolism and decrease protein catabolism. Nitrogen balance is improved only when there is sufficient intake of calories and protein.

Androgens are responsible for the growth spurt of adolescence and the termination of linear growth, caused by the fusion of the epiphyseal growth centers. In children, exogenous androgens accelerate linear growth rates, but can cause a disproportionate progression of bone maturation. Use over long periods of time may cause the epiphyseal growth centers to fuse and the growth process to stop. Androgens have been reported to stimulate the production of red blood cells by increasing the production of erythropoietic stimulating factor.

During exogenous administration of androgens, endogenous testosterone release is inhibited by inhibiting the pituitary luteinizing hormone (LH) response. At high doses of exogenous androgens, spermatogenesis may also be suppressed by inhibiting the pituitary pituitary hormone (FSH) response.

There is a lack of substantial evidence that androgens are effective in fractures, surgery, convalescence, and functional uterine bleeding.

INDICATION in Belgium

TESTO-CYPMAX (testosterone cypionate) injection is indicated for replacement therapy in males in conditions associated with symptoms of deficiency or absence of endogenous testosterone.

Primary hypogonadism (congenital or acquired) testicular failure due to cryptorchidism, bilateral torsion, orchitis, testicular disappearance syndrome, or orchiectomy.

Hypogonadotropic hypogonadism (congenital or acquired) idiopathic gonadotropin or LHRH deficiency, or pituitary-hypothalamic lesion from tumors, trauma, or radiation.